Brown Advisory Inc Seagen Inc. Transaction History

Brown Advisory Inc

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 24, 2023	SELL	$191.51 - $216.16 $44,047 - $49,716	-230 Reduced 1.42%	16,014 $3.4 Million
Q2 2023 Jul 31, 2023	SELL	$187.64 - $206.25 $9,382 - $10,312	-50 Reduced 0.31%	16,244 $3.13 Million
Q1 2023 May 08, 2023	BUY	$127.59 - $203.08 $9,824 - $15,637	77 Added 0.47%	16,294 $3.3 Million
Q4 2022 Feb 13, 2023	SELL	$117.37 - $139.17 $200,937 - $238,259	-1,712 Reduced 9.55%	16,217 $2.08 Million
Q3 2022 Nov 14, 2022	BUY	$135.27 - $180.11 $54,108 - $72,044	400 Added 2.28%	17,929 $2.45 Million
Q2 2022 Nov 14, 2022	SELL	$108.81 - $179.33 $1,632 - $2,689	-15 Reduced 0.09%	17,529 $3.1 Million
Q2 2022 Sep 13, 2022	BUY	$108.81 - $179.33 $126,763 - $208,919	1,165 Added 7.12%	17,529 $3.1 Million
Q2 2022 Aug 02, 2022	SELL	$108.81 - $179.33 $1,632 - $2,689	-15 Reduced 0.09%	16,364 $2.9 Million
Q1 2022 Nov 14, 2022	BUY	$119.61 - $157.85 $1,794 - $2,367	15 Added 0.09%	17,544 $2.53 Million
Q1 2022 May 09, 2022	SELL	$119.61 - $157.85 $2,751 - $3,630	-23 Reduced 0.14%	16,379 $2.36 Million
Q4 2021 Jan 27, 2022	BUY	$142.57 - $190.86 $7,271 - $9,733	51 Added 0.31%	16,402 $2.54 Million
Q3 2021 Nov 12, 2021	SELL	$142.45 - $169.82 $202,278 - $241,144	-1,420 Reduced 7.99%	16,351 $2.78 Million
Q2 2021 Jul 29, 2021	SELL	$135.08 - $161.1 $101,039 - $120,502	-748 Reduced 4.04%	17,771 $2.81 Million
Q1 2021 May 14, 2021	BUY	$137.51 - $190.8 $24,201 - $33,580	176 Added 0.96%	18,519 $2.57 Million
Q4 2020 Feb 12, 2021	BUY	$164.63 - $211.93 $3.02 Million - $3.89 Million	18,343 New	18,343 $3.21 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Brown Advisory Inc, based on Form 13F filings with the SEC.

Stay updated on Brown Advisory Inc with notifications on news.